Although RPLS induced by a targeted drug, such as bevacizumab, is rare, given the gradual popularization of targeted drugs and gradual recognition of RPLS, the incidence of RPLS may increase in the future. RPLS can be classified as an acute complication associated with cancer treatment, and the diagnosis and treatment of RPLS can be standardized. A diagnosis can be obtained through clinical presentation and typical MRI images. The principle of treatment involves stopping the drug immediately and providing aggressive treatment for normotension. The prognosis of the vast majority of cases is good. There are few reports on whether RPLS will relapse if the patient continues to take the medicine. In this case, the patient continued to take apatinib at half the dose 1 week later. She did not experience RPLS again. The cause was unknown. Perhaps it was an open question.
1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. ;N End J Med. 1996;334(8):494–500.
2. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. ;Lancet Neurol. 2015;14(9):914–925.
3. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. ;Arch Neurol. 2008;65(2):205–210.
4. Tlemsani C, Mir O, Psimaras D, et al. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agent: Clinical experience in Paris University Hospitals. ;Eur J Cancer. 2016;66:75–82.
5. Singer S, Grommes C, Reiner AS, Rosenblum MK, Deangelis LM. Posterior reversible encephalopathy syndrome in patients with Cancer. ;Oncologist. 2015;20(7):806–811.
6. Femia G, Hardy TA, Spies JM, et al. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. ;Asia Pac J Clin Oncol. 2012;8(2):115–122.
7. Dedić Plavetić N, Rakušić Z, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. ;World J Surg Oncol. 2014;20(12):264.
8. Xie C, Jones VT. Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: a case report and literature review. ;Oncol Lett. 2016;11(2):1512–1516.
9. Maeda T, Kikuchi E, Matsumoto K, et al. Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient. ;Int J Clin Oncol. 2010;15(5):508–811.
10. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. ;N Engl J Med. 2006;354(9):980–982.
11. Massey J. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU. ;J Clin Neurosci. 2017;40:57–59.
12. Sclafani F, Gullo G, Mezynksi J, Collins C, Crown J. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. ;J Clin Oncol. 2012;30(26):257–259.
13. Furubayashi N, Negishi T, Iwai H, Nagase K, Nakamura M. Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: a report of two cases. ;Mol Clin Oncol. 2017;7(2):281–284.
14. Saraceno L, Ricigliano VAG, Cavalli M, et al. Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report. ;Neurol Sci. 2017;38(6):1119–1121.
15. Chelis L, Souftas V, Amarantidis K, et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. ;BMC Cancer. 2012;22(12):489.
16. Levy A, Benmoussa L, Ammari S, Albiges L, Escudier B. Reversible posterior leukoencephalopathy syndrome induced by axitinib. ;Clin Genitourin Cancer. 2014;12(1):33–34.
17. Kim CA, Price-Hiller J, Chu QS, et al. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. ;Invest New Drugs. 2014;32(5):1036–1045.
18. Garg RK. Posterior leukoencephalopathy syndrome. ;Postgrad Med J. 2001;77:24–28.
19. Karia SJ, Rykken JB, McKinney ZJ, Zhang L, McKinney AM. Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. ;AJNR Am J Neuroradiol. 2016;37(3):415–422.
20. Rykken JB, McKinney AM. Posterior reversible encephalopathy syndrome. ;Semin Ultrasound CT MR. 2014;35(2):118–135.
21. Dinsdale HB, Robertson DM, Haas RA. Cerebral blood flow in acute hypertension. ;Arch Neurol. 1974;31(2):80–87.
22. Truwit CL, Denaro CP, Lake JR, DeMarco T. MR imaging of reversible cyclosporin A-induced neurotoxicity. ;AJNR Am J Neuroradiol. 1991;12(4):651–659.
23. Shankar J, Banfield J. Posterior reversible encephalopathy syndrome: a review. ;Can Assoc Radiol J. 2017;68(2):147–153.
Source: OncoTargets and Therapy.
Originally published July 30, 2018.